Tysabri and PML: What Washington Patients Should Know About Reporting and Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Risk Awareness

If you or a loved one has taken Tysabri and are now concerned about symptoms like confusion, weakness, or vision changes, understanding the difference between MS relapse and PML is critical. The medical community has long recognized the need for clear patient education and adverse event tracking to improve outcomes. This guide explains how PML is diagnosed, what monitoring steps are recommended, and how to report concerns in Washington.

Find Out If You Qualify for Compensation →

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis in adults (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by reactivation of the John Cunningham virus (JCV). The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning underscores the gravity of PML as a potential outcome for patients receiving Tysabri. Clinical presentation of PML typically includes subacute neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. Diagnosis relies on brain magnetic resonance imaging (MRI) showing characteristic white matter lesions, along with detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction (PCR). The FDA adverse event reporting system (FAERS) data for Tysabri lists cognitive disorder (3478 reports), memory impairment (7895 reports), and gait disturbance (9422 reports) among the most frequently reported adverse events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms are not exclusive to PML, they overlap with early PML manifestations, making clinical vigilance essential.

Mechanism of PML Development and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri blocks lymphocyte adhesion and migration across the blood-brain barrier, reducing immune surveillance within the central nervous system. This immunosuppressive effect allows latent JCV, which is carried asymptomatically by a majority of adults, to reactivate and infect oligodendrocytes, leading to demyelination and neuronal damage. The FDA boxed warning identifies three key risk factors for PML development: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Anti-JCV antibody seropositivity indicates prior exposure to the virus, while longer treatment duration (especially beyond two years) and previous immunosuppressant use further elevate risk. The adequacy of warnings regarding Tysabri and PML is a central issue in legal contexts. The FDA-required boxed warning is prominently displayed in the prescribing information, and the drug is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Under this program, patients must read a Medication Guide, understand the risks, and sign an enrollment form. Healthcare professionals are instructed to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether prescribers adequately communicated the risk of PML to patients, particularly in cases where early symptoms were overlooked or misattributed to multiple sclerosis relapse.

Statute of Limitations for Tysabri Claims in Washington

For patients in Washington who have developed PML after Tysabri exposure, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Washington, the statute of limitations for personal injury claims generally is three years from the date the injury was discovered or reasonably should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can be variable. PML typically develops after months to years of treatment, with the FDA boxed warning noting that duration of therapy is a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The onset of neurological symptoms may be gradual, and definitive diagnosis often requires MRI and CSF analysis, which can delay recognition. This latency period complicates the determination of when the statute of limitations begins to run. Affected individuals should consult with legal counsel promptly to assess their specific circumstances, as failure to file within the statutory period may bar recovery. In summary, Tysabri-associated PML is a serious, often devastating condition with a well-characterized risk profile. The FDA has mandated robust warnings and a restricted distribution program to mitigate this risk, but cases continue to occur. For patients in Washington, understanding the statute of limitations and seeking timely legal advice is critical. The evidence underscores the importance of early recognition of PML symptoms and the need for clear communication between healthcare providers and patients regarding the risks of Tysabri therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Washington?

In Washington, the statute of limitations for personal injury claims, including those related to Tysabri and PML, is generally three years from the date the injury was discovered or reasonably should have been discovered. Due to the delayed onset of PML symptoms, it is crucial to consult an attorney promptly to determine the applicable deadline.

What are the key risk factors for developing PML while on Tysabri?

The FDA boxed warning identifies three key risk factors: the presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients should discuss these risks with their healthcare provider.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.